With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...